Resorptive Hypercalcemia in Post-Essential Thrombocythemia Myelofibrosis: Treatment with Denosumab

Nadia Khoury; Julietta Chang; Alejandro A. Gru; Michael P. Whyte

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Resorptive Hypercalcemia in Post-Essential Thrombocythemia Myelofibrosis: Treatment with Denosumab

【24h】

Resorptive Hypercalcemia in Post-Essential Thrombocythemia Myelofibrosis: Treatment with Denosumab

机译：实质性血小板增多性骨髓纤维化后吸收性高钙血症：地诺单抗治疗

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Context:Hypercalcemia associated with myelofibrosis is rare, and its pathogenesis and treatment are not known.

机译：背景：伴有骨髓纤维化的高钙血症罕见，其发病机理和治疗方法尚不清楚。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2012年第9期|共5页
作者
Nadia Khoury; Julietta Chang; Alejandro A. Gru; Michael P. Whyte;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment [J] . G Barosi, R A Mesa, J Thiele, Leukemia . 2008,第2期

机译：拟议的诊断标准，用于后囊肿后Vera和后基本血小板血症肌肌纤维化：肌电纤维化研究和治疗国际工作组的共识声明
2. The Evolving Understanding of Prognosis in Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis [J] . Lucia Masarova, Srdan Verstovsek Clinical advances in hematology & oncology: H&O . 2019,第5期

机译：在基本基本血小板血症和多胆后血症后的预后的不断变化的理解Vera Myelofibris对原发性髓颤
3. Population pharmacokinetic analysis of orally-administered ruxolitinib (incb018424 phosphate) in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF) [J] . ChenX., WilliamsW.V., SandorV., The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2013,第7期

机译：原发性骨髓纤维化（pmf），真性红细胞增多症后真性骨髓纤维化（PPV-MF）或实质性血小板增多性骨髓炎（PET MF）患者口服ruxolitinib（incb018424磷酸盐）的群体药代动力学分析
4. Neurokinin-1 As a Potential Target for the Treatment of Myelofibrosis [C] . P.S. Bandari, H.S. Oh, C. Yook J.A. Potian, European Haematology Association . 2002

机译：Neurokinin-1作为治疗骨髓纤维化的潜在目标
5. Environmental Etiology of Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis: A Case-Control Study in Northeast Pennsylvania. [D] . Gross-Davis, Carol Ann. 2014

机译：真性红细胞增多症，原发性血小板增多症和原发性骨髓纤维化的环境病因：宾夕法尼亚州东北部的病例对照研究。
6. Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis [O] . A Tefferi, L Saeed, C A Hanson, -1

机译：当前原发性骨髓纤维化的预后模型在真性红细胞增多症或实质性血小板增多性骨髓纤维化之后的应用
7. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment [O] . Barosi G, Mesa RA, Thiele J, 2008

机译：诊断真性红细胞增多症和原发性血小板增多症后骨髓纤维化的建议标准：国际骨髓纤维化研究和治疗工作组的共识声明

Resorptive Hypercalcemia in Post-Essential Thrombocythemia Myelofibrosis: Treatment with Denosumab

摘要

著录项

相似文献

相关主题

期刊订阅